Zonnic Mint lozenge and Zonnic Pepparmint oromucosal spray ENG PAR
ثبت نشده
چکیده
منابع مشابه
Zonnic®: a new player in an old field
The tobacco industry is continually evolving to adapt to increasing tobacco control pressure and regulation, and to cater to consumer preferences. Recently, RJ Reynolds rolled-out a nicotine-containing gum, Zonnic®, which is marketed as a smoking cessation and reduction product and is sold at convenience stores at a lower price and in a smaller quantity than existing brands sold at pharmacies. ...
متن کاملNew Product Marketing Blurs the Line Between Nicotine Replacement Therapy and Smokeless Tobacco Products.
Tobacco companies have begun to acquire pharmaceutical subsidiaries and recently started to market nicotine replacement therapies, such as Zonnic nicotine gum, in convenience stores. Conversely, tobacco companies are producing tobacco products such as tobacco chewing gum and lozenges that resemble pharmaceutical nicotine replacement products, including a nicotine pouch product that resembles sn...
متن کاملAdvances in the management of multiple sclerosis spasticity: recent clinical trials.
BACKGROUND Most patients with multiple sclerosis (MS) experience spasticity as the clinical course evolves. Associated symptoms include (often painful) spasms, urinary dysfunction and sleep disturbances. THC:CBD oromucosal spray (Sativex®) is approved for symptom improvement in adult patients with moderate to severe MS-related spasticity who have not responded adequately to other antispasticity...
متن کاملEffects of nicotine mouth spray on urges to smoke, a randomised clinical trial
OBJECTIVE A new nicotine mouth spray was shown to be an effective stop-smoking treatment. This study was set up to examine the speed with which it relieves urges to smoke, and how it compares with nicotine lozenge in this respect. DESIGN Randomised, cross-over trial that compared nicotine mouth spray 2 mg versus nicotine lozenge 2 or 4 mg. SETTING Clinical pharmacology research unit. PART...
متن کاملTHC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
BACKGROUND From the time Sativex (THC:CBD) oromucosal spray first became available in European Union countries in 2010 for the management of treatment-resistant multiple sclerosis (MS) spasticity, data from daily practice have been collected through various projects. METHODS A retrospective registry study and a prospective safety study of THC:CBD oromucosal spray are reported. RESULTS The m...
متن کامل